171 related articles for article (PubMed ID: 11429124)
1. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.
Ross TM; Xu Y; Green TD; Montefiori DC; Robinson HL
AIDS Res Hum Retroviruses; 2001 Jun; 17(9):829-35. PubMed ID: 11429124
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.
Green TD; Montefiori DC; Ross TM
J Virol; 2003 Feb; 77(3):2046-55. PubMed ID: 12525639
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
4. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
[TBL] [Abstract][Full Text] [Related]
5. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.
Liu F; Mboudjeka I; Shen S; Chou TH; Wang S; Ross TM; Lu S
Vaccine; 2004 Apr; 22(13-14):1764-72. PubMed ID: 15068860
[TBL] [Abstract][Full Text] [Related]
6. Mouse strain-dependent differences in enhancement of immune responses by C3d.
Toapanta FR; Ross TM
Vaccine; 2004 Apr; 22(13-14):1773-81. PubMed ID: 15068861
[TBL] [Abstract][Full Text] [Related]
7. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.
Bower JF; Yang X; Sodroski J; Ross TM
J Virol; 2004 May; 78(9):4710-9. PubMed ID: 15078953
[TBL] [Abstract][Full Text] [Related]
8. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
[TBL] [Abstract][Full Text] [Related]
9. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.
Richmond JF; Lu S; Santoro JC; Weng J; Hu SL; Montefiori DC; Robinson HL
J Virol; 1998 Nov; 72(11):9092-100. PubMed ID: 9765454
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
[TBL] [Abstract][Full Text] [Related]
12. C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.
Bower JF; Sanders KL; Ross TM
Curr HIV Res; 2005 Apr; 3(2):191-8. PubMed ID: 15853723
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.
Nayak BP; Sailaja G; Jabbar AM
J Virol; 2003 Oct; 77(20):10850-61. PubMed ID: 14512535
[TBL] [Abstract][Full Text] [Related]
14. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.
Ross TM; Xu Y; Bright RA; Robinson HL
Nat Immunol; 2000 Aug; 1(2):127-31. PubMed ID: 11248804
[TBL] [Abstract][Full Text] [Related]
15. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
16. A minimum CR2 binding domain of C3d enhances immunity following vaccination.
Bower JF; Ross TM
Adv Exp Med Biol; 2006; 586():249-64. PubMed ID: 16893077
[TBL] [Abstract][Full Text] [Related]
17. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
Corbet S; Vinner L; Hougaard DM; Bryder K; Nielsen HV; Nielsen C; Fomsgaard A
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1997-2008. PubMed ID: 11153083
[TBL] [Abstract][Full Text] [Related]
18. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.
Chakrabarti BK; Kong WP; Wu BY; Yang ZY; Friborg J; Ling X; King SR; Montefiori DC; Nabel GJ
J Virol; 2002 Jun; 76(11):5357-68. PubMed ID: 11991964
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
20. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
